Business Profile & Competitive Position
Intuitive Surgical, Inc. operates in the Healthcare sector under the Medical - Instruments & Supplies industry. Its business is built around robotic-assisted surgical platforms and the recurring revenue stream from instruments, accessories, and services tied to those installed systems. That model matters because a large installed base of machines creates high switching costs for hospitals and surgeons, and consumable sales repeat every procedure rather than requiring a new capital sale.
The margin and return figures in the latest data support that interpretation. A 28.4% net margin is well above what commodity-like medical-supply businesses typically generate, suggesting pricing power and a differentiated product set. The 17.8% ROE shows that the company is turning shareholder equity into profits efficiently. Together, those numbers point to a competitive position that is stronger than a simple equipment vendor, though the company's premium valuation also means it has to keep executing at a high level.
Financial Posture
Intuitive Surgical currently carries a $132.7 billion market cap and trades at a trailing P/E of 42.4. That multiple is high relative to the broader Healthcare sector and reflects the market's willingness to pay a premium for above-average growth, margins, and the long runway of robotic surgery adoption.
The profitability profile remains the anchor: 28.4% net margin and 17.8% ROE confirm that earnings quality is strong. The stock's beta of 1.47 tells a different side of the story: ISRG tends to move more sharply than the overall market in both directions. The current snapshot shows the price at $375.565, just below the 50-day EMA of $380.41, with an RSI of 51.0—a neutral reading after a modest pullback from the moving average.
Looking ahead, the next earnings release is scheduled for October 20, 2026, before the market open, with the published consensus EPS estimate at $2.61. No debt figure was included in the latest data snapshot, so any leverage assessment should wait for the full filings.
Macro & Geopolitical Exposure
Because Intuitive Surgical sits in the Medical - Instruments & Supplies industry, its exposures are those that typically affect medical-device companies:
- Regulatory risk: New systems, indications, and software updates usually require FDA clearance or equivalent overseas approvals, which can affect launch timing and R&D returns.
- Reimbursement risk: Hospital purchasing decisions depend on Medicare, Medicaid, and private-payer coverage for robotic-assisted procedures. Any reimbursement cuts or delayed coverage decisions can slow procedure growth and capital spending.
- Trade and tariff exposure: Instruments and components often cross multiple borders, so changes in tariffs or trade restrictions can affect manufacturing costs and margins.
- China and international pressure: China is a significant growth market for many medical-device firms, but it is also politically sensitive and subject to local tender rules, pricing pressure, and potential retaliation risk.
- Currency translation: A meaningful portion of revenue comes from outside the U.S., so a stronger dollar can compress reported results even when local demand is healthy.
Recent Developments
The most recent headlines bracket the key debate around ISRG right now: strong underlying procedure demand but macro headwinds in the U.S. and China.
- On September 13, 2026, 247wallst.com reported that Goldman Sachs now sees 6.5 million humanoid robots by 2035, a broader robotics backdrop that keeps investor attention on automation and surgical-robot platforms.
- On September 11, 2026, marketbeat.com noted that Intuitive Surgical sees procedure growth despite U.S. slowdown and China pressure. That headline aligns with the bull case: demand for robotic-assisted surgery is resilient even where capital budgets look tight.
- Also on September 11, 2026, marketbeat.com published "This AI ETF Is Missing the Biggest AI Winners," a reminder that much of the robotics and AI narrative is happening inside individual companies rather than broad thematic ETFs.
- On September 9, 2026, seekingalpha.com carried the Wells Fargo 21st Annual Healthcare Conference transcript for Intuitive Surgical, giving investors a direct look at management commentary around procedure growth, customer utilization, and capital placement.
Earnings Behavior & Post-Earnings Drift
Intuitive Surgical's earnings track record is statistically impressive. Over the last eight reported quarters, the company has beaten the consensus EPS estimate 8 times out of 8, for a 100% beat rate. The average earnings surprise across those quarters is 14.1%. On the surface, that looks like a consistent setup for post-earnings upside.
The reality is more complicated. The average 5-day price move after earnings across those same quarters is just 0.08%, classified as flat. That means the bullish surprises have not reliably translated into a directional drift.
The last four reports show exactly why "beat equals pop" is a dangerous assumption:
- July 16, 2026: EPS of $2.80 beat the $2.48 estimate by 12.9%, yet the stock fell 14.15% the next day and 17.48% over the next five days.
- April 21, 2026: EPS of $2.80 beat the $2.51 estimate by 11.6%, and the stock rose 7.16% the next day and 3.4% over five days.
- January 22, 2026: EPS of $2.53 beat the $2.27 estimate by 11.5%, but the stock slipped 0.35% the next day and 3.47% over five days.
- October 21, 2025: EPS of $2.40 beat the $1.99 estimate by 20.6%, and the stock jumped 13.89% the next day and 17.86% over five days.
The disconnect makes sense once expectations are factored in. Because ISRG beats so regularly, the market's real expectation may already be priced above the published consensus. Guidance, valuation compression, and macro concerns can override the headline beat. For the October 20, 2026 report, the consensus EPS estimate is $2.61, but the reaction will likely hinge on any outlook commentary as much as the print itself.
Frequently Asked Questions
What do Intuitive Surgical's 28.4% net margin and 17.8% ROE indicate about its competitive position?
Those figures suggest strong pricing power and a recurring-revenue business model. The high net margin points to differentiated products, while the double-digit ROE shows the company is generating solid returns on shareholder equity.
Has ISRG consistently beaten earnings estimates?
Yes. Intuitive Surgical has beaten the consensus EPS estimate in each of the last eight reported quarters, with an average earnings surprise of 14.1%.
Why did ISRG fall sharply after its July 2026 earnings beat?
On July 16, 2026, ISRG beat the $2.48 estimate by 12.9% with EPS of $2.80, but the stock fell 14.15% the next day and 17.48% over the following five days. That illustrates how guidance, valuation expectations, and broader market sentiment can matter more than the headline beat alone.
For a deeper dive into how institutional analysts are interpreting Intuitive Surgical's valuation, guidance risks, and earnings setup ahead of the October 20, 2026 report, review the full institutional verdict and consensus breakdowns available on the platform.
| Reported | Actual | Estimate | Surprise | 1D Move | 5D Move |
|---|---|---|---|---|---|
| 2026-07-16 | $2.8 | $2.48 | +12.9% | -14.15% | -17.48% |
| 2026-04-21 | $2.8 | $2.51 | +11.6% | +7.16% | +3.4% |
| 2026-01-22 | $2.53 | $2.27 | +11.5% | -0.35% | -3.47% |
| 2025-10-21 | $2.4 | $1.99 | +20.6% | +13.89% | +17.86% |
| 2025-07-22 | $2.19 | $1.93 | +13.5% | - | - |
| 2025-04-22 | $1.81 | $1.74 | +4% | - | - |
Previous ISRG editions
Get the institutional verdict on ISRG
Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.
Read the ISRG verdict at Gamma QCVerify authenticity
Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.